{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
US Previously Marketed
Source:
Sulfapyrazine by Mead Johnson
(1944)
Source URL:
First approved in 1944
Source:
Sulfapyrazine by Mead Johnson
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Previously Marketed
First approved in 1944
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
FURTRETHONIUM is an agonist of muscarinic acetylcholine receptors. It was used for the treatment of glaucoma.
Status:
US Previously Marketed
Source:
AMINOHIPPURATE SODIUM by MERCK
(1944)
Source URL:
First approved in 1944
Source:
AMINOHIPPURATE SODIUM by MERCK
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Aminohippurate (p-aminohippuric acid, PAH, PAHA) is the glycine amide of p-aminobenzoic acid. Aminohippuric acid sodium salt is an agent to measure effective renal plasma flow (ERPF).
Status:
US Previously Marketed
Source:
DICUMAROL by ABBVIE
(1944)
Source URL:
First approved in 1944
Source:
DICUMAROL by ABBVIE
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Dicumarol is an coumarin-like compound found in sweet clover. It is used as oral anticoagulant and acts by inhibiting the hepatic synthesis of vitamin K-dependent coagulation factors (prothrombin and factors VII, IX, and X). It results in decresed prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots. Dicumarol is also used in biochemical experiments as an inhibitor of reductases.
Status:
First approved in 1944
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Carbarsone is an antiambeic, antihistomonal drug effective in controlling and preventing blackhead disease in turkeys (a disease caused by a protozoan parasite Histomonas meleagridis). Carbarsone was approved by FDA, however, it has not been marketed in the USA scince 1996.
Status:
First approved in 1944
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Previously Marketed
Source:
PANTOPAQUE by ALCON
(1944)
Source URL:
First approved in 1944
Source:
PANTOPAQUE by ALCON
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2009)
First approved in 1944
Class:
STRUCTURALLY DIVERSE
Conditions:
Immune globulin human (Human immunoglobulin) is a mixture of IgG1 and other antibodies derived from healthy human plasma and used to strengthen the body's natural defense system (immune system) to reduce the risk of infection in people with weakened immune systems. Human immunoglobulin is used as replacement therapy for inherited humoral immunodeficiency disorders, such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich syndrome. Human immunoglobulin interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors, and several immunocompetent cell surface molecules. Human immunoglobulin also acts on various effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Human immune globulin competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and inhibiting platelet depletion. Human immunoglobulin contains a number of different antibodies that prevent infection by attaching pathogenic microorganisms to the surface and facilitating their removal before they can infect cells. Antibodies remove pathogens by activating complement, agglutination or precipitation, blocking the pathogen receptor, “tagging” macrophages, or neutralizing the pathogen toxins. Serious adverse reactions are observed during intravenous treatment in clinical studies of aseptic meningitis. The most common adverse reactions were headache, fatigue, hyperthermia, nausea, chills, severity, pain in the limbs, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, sore throat and throat, rash, myalgia, itching, and cardiac murmur. During clinical trials of subcutaneous treatment, no serious adverse reactions were observed.
Status:
US Previously Marketed
First approved in 1944
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
FURTRETHONIUM is an agonist of muscarinic acetylcholine receptors. It was used for the treatment of glaucoma.
Status:
US Previously Marketed
First approved in 1944
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
FURTRETHONIUM is an agonist of muscarinic acetylcholine receptors. It was used for the treatment of glaucoma.